Global Access
Global Access
IAS 2017: Aim for $90-$90-$90 Target on HIV, Hepatitis, and TB Drug Prices, Study Says
- Details
- Category: HIV Treatment
- Published on Thursday, 17 August 2017 00:00
- Written by Keith Alcorn
HIV, hepatitis B and C, and tuberculosis (TB) can each be treated for less than $90 a year where generic drugs can be made available, Dzintars Gotham of Imperial College London reported at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.
IAS 2017: WHO Recommends Urgent Care Package for People with Advanced HIV Disease
- Details
- Category: HIV Treatment
- Published on Wednesday, 09 August 2017 00:00
- Written by Keith Alcorn
A new package of measures to ensure rapid initiation of antiretroviral treatment and diagnosis of opportunistic infections has been recommended by the World Health Organization (WHO) to reduce the still high rates of death among people diagnosed with HIV at a very advanced stage of disease.
CROI 2017: Accelerated Linkage to HIV Care Improves Retention by a Third
- Details
- Category: Global Access
- Published on Thursday, 13 April 2017 00:00
- Written by Carole Leach-Lemens
Close to 60% of adults benefitting from point-of-care CD4 cell count testing at HIV testing sites, accelerated antiretroviral therapy (ART) initiation, and SMS appointment reminders were retained in care after 1 year, compared to just 44% of those receiving the standard of care in Mozambique, according to findings from the Engage4Health study presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2017) in Seattle.
IAS 2017: Improved Cryptococcal Meningitis Treatment Could Save Thousands of Lives
- Details
- Category: Opportunistic Illness (OIs)
- Published on Wednesday, 09 August 2017 00:00
- Written by Keith Alcorn
Urgent action is needed to improve access to the antifungal drug flucytosine, say investigators, following the presentation of the results of a trial showing that treatment containing flucytosine is superior to any other form of therapy in reducing the risk of death from cryptococcal meningitis in people with very advanced HIV disease.
CROI 2017: Test and Treat Study Shows Second Phase Is Finding More People with HIV
- Details
- Category: Global Access
- Published on Thursday, 13 April 2017 00:00
- Written by Keith Alcorn
After a second wave of intensive household testing, a large study of the "test and treat" strategy in Zambia is diagnosing more people with HIV, getting more people onto treatment, and reducing the time between diagnosis and starting treatment, findings from the PopART study presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2017) show.
More Articles...
- CROI 2017: Peer Navigators Improve Linkage to HIV Care and Retention in South African Study
- CROI 2017: Point-of-Care Testing Improves Infant HIV Diagnosis Rate, Treatment, and Retention
- Donors Pledge $13 Billion to Replenish Global Fund
- AIDS 2016: Earlier HIV Treatment Is Not Over-burdening Health Services
- AIDS 2016: Infection Prophylaxis Reduces Risk of Death for People Starting HIV Treatment Late
Web Design and Development by